Skip to main content
Switching to decaf reduces caffeine-mediated drug interactions, but the timing of when you drink coffee relative to when you take medication often matters more than whether the coffee contains caffeine.

​
Levothyroxine (Thyroid Medication)

Levothyroxine is one of the most widely prescribed medications in the United States and one of the most studied in relation to coffee interference. A 2008 study by Benvenga et al., published in Thyroid (PMID 18341376), found that espresso consumed simultaneously with levothyroxine reduced peak serum T4 by 29 to 36% and reduced the area under the curve by 27 to 36%. When patients waited 60 minutes after taking levothyroxine before drinking coffee, no significant absorption effect was observed. A 2021 systematic review by Wiesner et al., published in Pharmaceuticals (DOI 10.3390/ph14030206), examined 63 studies and confirmed that coffee reduces levothyroxine absorption. The authors recommend a minimum 60-minute separation between levothyroxine and coffee. Here is the important caveat for decaf drinkers: the levothyroxine interaction is thought to occur through physical adsorption of the drug onto coffee particles, not through a caffeine-mediated mechanism. This means decaf coffee may carry the same absorption-reducing risk as regular coffee. No study has directly compared decaffeinated versus regular coffee for levothyroxine absorption. Until such a study exists, people taking levothyroxine should maintain the 60-minute separation regardless of whether their coffee is caffeinated or decaf.

​
Warfarin (Blood Thinner)

The interaction between caffeine and warfarin is biologically plausible and has been studied in animals. A 2018 study by Zafar and Ashraf, published in the Pakistan Journal of Pharmaceutical Sciences (PMID 29625932), found that caffeine inhibited warfarin metabolism in rabbits and increased INR. Human clinical evidence remains sparse. No high-quality randomized controlled trial has quantified a specific percentage change in INR attributable to coffee or caffeine in humans. Clinicians generally advise patients on warfarin to maintain consistent coffee intake rather than eliminating it, because sudden changes in consumption can shift INR values unpredictably. Decaf reduces caffeine intake to 2 to 15 mg per serving, compared to 80 to 100 mg in regular coffee. For patients on warfarin who want to reduce the caffeine variable, switching to decaf is a reasonable approach, but INR should still be monitored during any dietary transition. Discuss any change with the prescribing physician.

​
Stimulant ADHD Medications (Adderall, Vyvanse)

Caffeine and amphetamine-based medications such as Adderall and Vyvanse both stimulate the central nervous system. Combining them produces additive stimulant effects: elevated heart rate, increased blood pressure, heightened anxiety, and disrupted sleep. This is a pharmacological mechanism, not a drug-specific interaction unique to ADHD medications. No large-scale randomized controlled trial has been conducted to quantify the specific percentage increase in cardiovascular effects from combining caffeine with amphetamines in humans. The clinical guidance to limit caffeine during stimulant medication use is based on the known pharmacology and case-series reports of adverse effects. Decaf contains 2 to 15 mg of caffeine per serving. This dramatically reduces the additive stimulant variable compared to regular coffee at 80 to 100 mg. For patients on Adderall or Vyvanse who want to continue drinking coffee without compounding the stimulant burden, switching to decaf is a documented harm-reduction strategy.

​
The General Principle: Timing Matters

For absorption-sensitive medications, the key variable is the gap between taking the medication and drinking any coffee, decaffeinated or not. The Benvenga 2008 study showed that a 60-minute separation eliminated the levothyroxine interaction entirely, regardless of coffee strength. For medications sensitive to caffeine’s pharmacological effects, the key variable is caffeine dose. Decaf’s 2 to 15 mg per serving is substantially lower than the 80 to 100 mg in regular coffee, which reduces but does not eliminate the interaction.

​
What Colipse Coffee offers for people managing drug interactions

​
How each product helps when managing medications

Decaf Pods provide dose consistency. When caffeine interacts with a medication - whether by competing for CYP1A2 metabolism, displacing plasma protein binding, or adding to a CNS stimulant load - the interaction’s magnitude depends partly on how much caffeine is consumed. A pod delivers a predictable 2 to 15 mg residual caffeine per cup, removing the variability of grind size, brew time, and coffee-to-water ratio that makes drip or French press caffeine content unpredictable. Dark Roast Decaf eliminates the CYP1A2 substrate competition that is the most clinically relevant caffeine-drug interaction mechanism. Drugs including theophylline, clozapine, olanzapine, and mexiletine share the CYP1A2 metabolic pathway with caffeine. High caffeine intake slows their clearance and elevates plasma levels. Switching to decaf removes caffeine as a competing substrate, which is relevant for anyone on drugs with narrow therapeutic indices metabolized by CYP1A2.

​
Frequently Asked Questions

Possibly yes. The 2008 Benvenga study showed that espresso reduced levothyroxine peak serum T4 by 29 to 36%. The mechanism is physical adsorption onto coffee particles, not a caffeine effect. Because decaf still contains coffee particles, it may carry a similar absorption-reduction risk. No study has directly compared decaf versus regular coffee for this interaction. Until that research exists, people taking levothyroxine should wait at least 60 minutes after their dose before drinking any coffee, including decaf.
Consistent moderate consumption of decaf coffee is unlikely to cause clinically dangerous INR changes, but the human evidence base is thin. An animal study found that caffeine inhibited warfarin metabolism and raised INR in rabbits. Human data are insufficient to quantify a specific effect. The main guidance from clinicians is to keep coffee intake consistent, because sudden large changes in caffeine or coffee consumption can shift INR values. If you switch from regular to decaf, inform your anticoagulation clinic and have your INR checked during the transition period.
Decaf is generally considered lower-risk than regular coffee for people taking amphetamine-based stimulants, because it contains only 2 to 15 mg of caffeine per serving versus 80 to 100 mg in regular coffee. The additive CNS stimulant effect from 2 to 15 mg of caffeine is substantially smaller than from a full cup of regular coffee. No randomized controlled trial has tested this specific combination. Individual responses vary. Consult the prescribing physician before making any changes, and monitor heart rate and blood pressure during any dietary transition.

​
Disclaimer

This page is for educational purposes only and does not constitute medical advice. Drug interactions depend on individual health status, dosage, and timing. Always consult your prescribing physician or pharmacist before changing dietary habits that may affect your medications.